Stephen T. Oh

Hematology
660 S Euclid Ave
Saint Louis, MO 63110

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 138 publications

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Journal: Expert review of hematology
Published: June 19, 2026

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Journal: Lancet regional health. Americas
Published: March 25, 2026

Unfolded protein response signaling promotes myeloid cell production and cooperates with oncogenic mutation.

Unfolded protein response signaling promotes myeloid cell production and cooperates with oncogenic mutation.

Journal: Blood advances
Published: January 29, 2026

Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate.

Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate.

Journal: Cancer discovery
Published: January 11, 2026

Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.

Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.

Journal: Clinical lymphoma, myeloma & leukemia
Published: December 18, 2025

Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.

Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.

Journal: Blood
Published: December 05, 2025

Parallel Evolution of Leukemic Clones in Myeloproliferative Neoplasms.

Parallel Evolution of Leukemic Clones in Myeloproliferative Neoplasms.

Journal: Research square
Published: December 03, 2025

JAK2 V617F Myeloproliferative Neoplasms Support Parallel Evolution of Independent Leukemic Clones.

JAK2 V617F Myeloproliferative Neoplasms Support Parallel Evolution of Independent Leukemic Clones.

Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025

Unfolded protein response signaling promotes myeloid cell production and cooperates with oncogenic mutation.

Unfolded protein response signaling promotes myeloid cell production and cooperates with oncogenic mutation.

Journal: bioRxiv : the preprint server for biology
Published: September 18, 2025

A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies.

A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies.

Journal: Cell communication and signaling : CCS
Published: August 30, 2025

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Journal: NEJM evidence
Published: August 26, 2025
Showing 1-12 of 138

Last Updated: 09/26/2026